| Title : First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus - Wang_2021_Clin.Drug.Investig_41_999 |
| Author(s) : Wang L , Lu J , Zhou S , Zhao Y , Xie L , Zhou C , Chen J , Ding S , Xie D , Ding J , Yu Q , Shen H , Hao G , Shao F |
| Ref : Clin Drug Investig , 41 :999 , 2021 |
| Abstract : Wang_2021_Clin.Drug.Investig_41_999 |
| ESTHER : Wang_2021_Clin.Drug.Investig_41_999 |
| PubMedSearch : Wang_2021_Clin.Drug.Investig_41_999 |
| PubMedID: 34655432 |
Wang L, Lu J, Zhou S, Zhao Y, Xie L, Zhou C, Chen J, Ding S, Xie D, Ding J, Yu Q, Shen H, Hao G, Shao F (2021)
First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Clin Drug Investig
41 :999
Wang L, Lu J, Zhou S, Zhao Y, Xie L, Zhou C, Chen J, Ding S, Xie D, Ding J, Yu Q, Shen H, Hao G, Shao F (2021)
Clin Drug Investig
41 :999